Zacks: Brokerages Expect Audentes Therapeutics Inc (NASDAQ:BOLD) to Announce -$1.08 EPS

Analysts expect that Audentes Therapeutics Inc (NASDAQ:BOLD) will report ($1.08) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Audentes Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.23) and the highest estimate coming in at ($0.98). Audentes Therapeutics reported earnings of ($0.97) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 11.3%. The firm is expected to announce its next quarterly earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Audentes Therapeutics will report full year earnings of ($4.25) per share for the current fiscal year, with EPS estimates ranging from ($4.67) to ($3.64). For the next financial year, analysts forecast that the business will report earnings of ($4.38) per share, with EPS estimates ranging from ($5.03) to ($3.39). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Audentes Therapeutics.

Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.08) by $0.07. During the same quarter in the prior year, the company posted ($0.85) earnings per share.

Several research firms have recently weighed in on BOLD. HC Wainwright set a $48.00 target price on shares of Audentes Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 8th. ValuEngine raised shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 27th. BMO Capital Markets set a $47.00 target price on shares of Audentes Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Citigroup downgraded shares of Audentes Therapeutics from a “neutral” rating to a “sell” rating and boosted their target price for the stock from $28.00 to $32.00 in a research report on Friday, April 26th. Finally, William Blair reissued a “hold” rating on shares of Audentes Therapeutics in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $39.99.

In other news, Director Louis G. Lange sold 21,000 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $37.79, for a total value of $793,590.00. Following the completion of the sale, the director now directly owns 290,001 shares of the company’s stock, valued at approximately $10,959,137.79. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Matthew R. Patterson sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $34.04, for a total transaction of $680,800.00. Following the completion of the sale, the chief executive officer now directly owns 135,368 shares of the company’s stock, valued at $4,607,926.72. The disclosure for this sale can be found here. Insiders own 5.30% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in BOLD. Meeder Asset Management Inc. raised its holdings in shares of Audentes Therapeutics by 578.5% during the second quarter. Meeder Asset Management Inc. now owns 726 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 619 shares during the period. Aperio Group LLC acquired a new stake in shares of Audentes Therapeutics during the second quarter valued at approximately $46,000. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Audentes Therapeutics during the fourth quarter valued at approximately $92,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Audentes Therapeutics by 50.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 1,005 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Audentes Therapeutics by 34.5% during the fourth quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 1,700 shares during the period. 96.72% of the stock is owned by institutional investors and hedge funds.

Shares of BOLD traded up $0.93 during midday trading on Friday, hitting $33.88. The company had a trading volume of 334,055 shares, compared to its average volume of 511,680. The company’s 50 day moving average price is $37.03 and its 200 day moving average price is $35.88. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -9.96 and a beta of 1.70. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $41.65.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Further Reading: How to build a Fibonacci channel

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.